Insulin Resistance-Induced Platelet Hyperactivity and a Potential Biomarker Role of Platelet Parameters: A Narrative Review

References

• Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday W. Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest. 1979;63(5):1060–1065.
   PubMed Web of Science ®Google Scholar
• Gaspar RS, Trostchansky A, Paes AMDA. Potential role of protein disulfide isomerase in metabolic syndrome-derived platelet hyperactivity. Oxid Med Cell Longev. 2016;2016:2423547. doi:10.1155/2016/2423547
   PubMed Web of Science ®Google Scholar
• Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun. 1988;157(3):1190–1196. doi:10.1016/S0006-291X(88)81000-3
   PubMed Web of Science ®Google Scholar
• Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2009;19(6):440–449. doi:10.1016/j.numecd.2009.01.006
   PubMed Web of Science ®Google Scholar
• Touyz RM, Schiffrin EL. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. J Hypertens. 1994;12(11):1255–1263. doi:10.1097/00004872-199411000-00008
   PubMed Web of Science ®Google Scholar
• Trovati M, Anfossi G, Massucco P, et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes. 1997;46(5):742–749. doi:10.2337/diab.46.5.742
   PubMed Web of Science ®Google Scholar
• Trovati M, Paola M, Mattiello L, Piretto V, Mularoni E, Anfossi G. The insulin-induced increase of guanosine-3′, 5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes. 1996;45(6):768–770. doi:10.2337/diab.45.6.768
   PubMed Web of Science ®Google Scholar
• Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719. doi:10.1155/2011/742719
   PubMed Web of Science ®Google Scholar
• Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman J-WN. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004;279(5):3254–3264. doi:10.1074/jbc.M305474200
   PubMed Web of Science ®Google Scholar
• Hunter R, Hers I. Insulin/IGF‐1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost. 2009;7(12):2123–2130. doi:10.1111/j.1538-7836.2009.03637.x
   PubMed Web of Science ®Google Scholar
• Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436–2443. doi:10.1093/eurheartj/eht149
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Yki-Järvinen H, Turpeinen A, et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol. 2002;22(1):167–172. doi:10.1161/hq0102.101546
   PubMed Web of Science ®Google Scholar
• Mayfield RK, Halushka PV, Wohltmann HJ, et al. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985;34(11):1127–1133. doi:10.2337/diab.34.11.1127
   PubMed Web of Science ®Google Scholar
• Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G. Platelet activation in obesity and metabolic syndrome. Obes Rev. 2012;13(1):27–42. doi:10.1111/j.1467-789X.2011.00930.x
   PubMed Web of Science ®Google Scholar
• Rodriguez BAT, Johnson AD. Platelet measurements and type 2 diabetes: investigations in two population-based cohorts. Front Cardiovasc Med. 2020;7. doi:10.3389/fcvm.2020.00118
   Web of Science ®Google Scholar
• Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost. 2013;110(4):669–680. doi:10.1160/TH13-01-0075
   PubMed Web of Science ®Google Scholar
• Gerrits AJ, Gitz E, Koekman CA, Visseren FL, van Haeften TW, Akkerman JWN. Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica. 2012;97(8):1149. doi:10.3324/haematol.2011.054916
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Massucco P, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest. 2004;34(7):482–489. doi:10.1111/j.1365-2362.2004.01370.x
   PubMed Web of Science ®Google Scholar
• Russo I, Del Mese P, Doronzo G, et al. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin Chem. 2007;53(6):1053–1060. doi:10.1373/clinchem.2006.076208
   PubMed Web of Science ®Google Scholar
• Resnick LM. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme. J Am Soc Nephrol. 1992;3(4):S78. doi:10.1681/ASN.V34s78
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev. 2006;2(4):409–430. doi:10.2174/1573399810602040409
   PubMedGoogle Scholar
• Santilli F, Simeone P, Liani R, Davì G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015;120:28–39.
   PubMed Web of Science ®Google Scholar
• Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2(8):1282–1291. doi:10.1111/j.1538-7836.2004.00836.x
   PubMed Web of Science ®Google Scholar
• Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14(suppl 3):S233–S6. doi:10.1097/01.ASN.0000077408.15865.06
   PubMedGoogle Scholar
• Barale C, Russo I. Influence of cardiometabolic risk factors on platelet function. Int J Mol Sci. 2020;21(2):623. doi:10.3390/ijms21020623
   PubMed Web of Science ®Google Scholar
• Tang WH, Stitham J, Jin Y, et al. Aldose reductase–mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation. 2014;129(15):1598–1609. doi:10.1161/CIRCULATIONAHA.113.005224
   PubMed Web of Science ®Google Scholar
• Obydennyy SI, Sveshnikova AN, Ataullakhanov FI, Panteleev MA. Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. J Thromb Haemost. 2016;14(9):1867–1881. doi:10.1111/jth.13395
   PubMed Web of Science ®Google Scholar
• Pedreño J, Hurt-Camejo E, Wiklund O, Badimón L, Masana L. Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets: evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling. Atherosclerosis. 2001;155(1):99–112. doi:10.1016/S0021-9150(00)00545-1
   PubMed Web of Science ®Google Scholar
• Randriamboavonjy V. Mechanisms involved in diabetes-associated platelet hyperactivation. In: The Non-Thrombotic Role of Platelets in Health and Disease. IntechOpen; 2015.
   Google Scholar
• Fang KC, Cheng YL, Su CW, et al. Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. J Chin Med Assoc. 2017;80(3):125–132. doi:10.1016/j.jcma.2016.07.003
   PubMed Web of Science ®Google Scholar
• Randriamboavonjy V, Pistrosch F, Bölck B, et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and μ-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation. 2008;117(1):52–60. doi:10.1161/CIRCULATIONAHA.107.719807
   PubMed Web of Science ®Google Scholar
• Randriamboavonjy V, Isaak J, Elgheznawy A, et al. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Am J Hematol. 2012;120(2):415–423.
   Google Scholar
• Darley-Usmar V, Halliwell B. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Pharm Res. 1996;13(5):649–662. doi:10.1023/A:1016079012214
   PubMed Web of Science ®Google Scholar
• Cangemi R, Pignatelli P, Carnevale R, et al. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes. 2012;61(6):1626–1632. doi:10.2337/db11-1243
   PubMed Web of Science ®Google Scholar
• Lawson JA, FitzGerald GA, Rokach J. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999;274(35):24441–24444. doi:10.1074/jbc.274.35.24441
   PubMed Web of Science ®Google Scholar
• Singh I, Mok M, Christensen A-M, Turner AH, Hawley JA. The effects of polyphenols in olive leaves on platelet function. Nutr Metab Cardiovasc Dis. 2008;18(2):127–132. doi:10.1016/j.numecd.2006.09.001
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939–1945. doi:10.2337/diabetes.49.11.1939
   PubMed Web of Science ®Google Scholar
• E-GA M, Abdallah N, Eldars W. Mean platelet volume and platelet distribution width correlate with microvascular complications in Egyptian people with type 2 diabetes mellitus. Curr Diabetes Rev. 2021;17(8):8–15.
   Web of Science ®Google Scholar
• Bhanukumar M, Ramaswamy PK, Peddi NK, Menon VB. Mean platelet volume and platelet distribution width as markers of vascular thrombosis in type 2 diabetes mellitus. J Postgrad Med. 2016;50(3):127–131. doi:10.5005/jp-journals-10028-1204
   Google Scholar
• Park JM, Lee JW, Shim JY, Lee YJ. Relationship between platelet count and insulin resistance in Korean adolescents: a nationwide population-based study. Metab Syndr Relat Disord. 2018;16(9):470–476. doi:10.1089/met.2018.0016
   PubMed Web of Science ®Google Scholar
• Joshi A, Jaison J. Study of platelet parameters-mean platelet volume (mpv) and platelet distribution width (PDW) in type 2 diabetes mellitus. Ann Path Lab Med. 2020;2020:6.
   Google Scholar
• Ding Q, Wang F, Guo X, Liang M. The relationship between mean platelet volume and metabolic syndrome in patients with type 2 diabetes mellitus: a retrospective study. Medicine. 2021;100(13):e25303. doi:10.1097/MD.0000000000025303
   PubMed Web of Science ®Google Scholar
• Braester A, Shturman A, Raviv B, Dorosinsky L, Rosental E, Atar S. What a family doctor should know about incidental finding of high mean platelet volume, metabolic syndrome, and pre-diabetes. Isr Med Assoc J. 2021;23(11):699–702.
   PubMed Web of Science ®Google Scholar
• Nardin M, Verdoia M, Barbieri L, De Luca G. Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease. Platelets. 2019;30(5):615–623. doi:10.1080/09537104.2018.1499885
   PubMed Web of Science ®Google Scholar
• Baldane S, Ipekci SH, Kebapcilar A. Relationship between insulin resistance and mean platelet volume in gestational diabetes mellitus. J Lab Physicians. 2015;7(2):112–115. doi:10.4103/0974-2727.163134
   PubMedGoogle Scholar
• Zhao F, Yan Z, Meng Z. Relationship between mean platelet volume and metabolic syndrome in Chinese patients. Sci Rep. 2018;8(1):14574. doi:10.1038/s41598-018-32751-1
   PubMedGoogle Scholar
• Sansanayudh N, Muntham D, Yamwong S, Sritara P, Akrawichien T, Thakkinstian A. The association between mean platelet volume and cardiovascular risk factors. Eur J Intern Med. 2016;30:37–42. doi:10.1016/j.ejim.2015.11.028
   PubMed Web of Science ®Google Scholar
• Noris P, Melazzini F, Balduini CL. New roles for mean platelet volume measurement in the clinical practice? Platelets. 2016;27(7):607–612. doi:10.1080/09537104.2016.1224828
   PubMed Web of Science ®Google Scholar
• Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509–1515. doi:10.1111/j.1742-1241.2009.02070.x
   PubMed Web of Science ®Google Scholar
• Kebapcilar L, Kebapcilar AG, Ilhan TT, et al. Is the mean platelet volume a predictive marker of a low apgar score and insulin resistance in gestational diabetes mellitus? A retrospective case-control study. Oxid Med Cell Longev. 2016;10(10):Oc06–oc10.
   Google Scholar
• Yang X-J, Zhang L-Y, Q-H M, et al. Platelet parameters in Chinese older adults with metabolic syndrome. Endocr Connect. 2020;9(7):696–704. doi:10.1530/EC-20-0209
   PubMed Web of Science ®Google Scholar
• Shah B, Sha D, Xie D, Mohler ER, Berger JS. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the national health and nutrition examination survey, 1999–2004. Diabetes Care. 2012;35(5):1074–1078. doi:10.2337/dc11-1724
   PubMed Web of Science ®Google Scholar
• Furman-Niedziejko A, Rostoff P, Rychlak R, et al. Relationship between abdominal obesity, platelet blood count and mean platelet volume in patients with metabolic syndrome. Folia Med Cracov. 2014;54(2):55–64.
   PubMedGoogle Scholar
• Lim HJ, Seo MS, Shim JY, Kim KE, Shin YH, Lee YJ. The association between platelet count and metabolic syndrome in children and adolescents. Platelets. 2015;26(8):758–763. doi:10.3109/09537104.2014.995613
   PubMed Web of Science ®Google Scholar
• Kim SH, Reaven G. Obesity and insulin resistance: an ongoing saga. Diabetes. 2010;59(9):2105–2106. doi:10.2337/db10-0766
   PubMed Web of Science ®Google Scholar
• Maury E, Brichard SM, Pataky Z, Carpentier A, Golay A, Bobbioni‐Harsch E. Effect of obesity on growth‐related oncogene factor‐α, thrombopoietin, and tissue inhibitor metalloproteinase‐1 serum levels. Obesity. 2010;18(8):1503–1509. doi:10.1038/oby.2009.464
   PubMedGoogle Scholar
• Chen YL, Hung YJ, He CT, et al. Platelet count can predict metabolic syndrome in older women. Platelets. 2015;26(1):31–37. doi:10.3109/09537104.2014.880415
   PubMed Web of Science ®Google Scholar
• Karamouzis I, Pervanidou P, Berardelli R, et al. Enhanced oxidative stress and platelet activation combined with reduced antioxidant capacity in obese prepubertal and adolescent girls with full or partial metabolic syndrome. Horm Metab Res. 2011;43(09):607–613. doi:10.1055/s-0031-1284355
   PubMedGoogle Scholar
• Karbiner MS, Sierra L, Minahk C, Fonio MC, de Bruno MP, Jerez S. The role of oxidative stress in alterations of hematological parameters and inflammatory markers induced by early hypercholesterolemia. Life Sci. 2013;93(15):503–508. doi:10.1016/j.lfs.2013.08.003
   PubMed Web of Science ®Google Scholar
• Bonaccio M, Di Castelnuovo A, De Curtis A, et al. Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. Am J Hematol. 2014;123(19):3037–3044.
   Google Scholar
• Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab Res Rev. 2015;31(4):402–410. doi:10.1002/dmrr.2625
   PubMed Web of Science ®Google Scholar
• Tzur I, Barchel D, Izhakian S, et al. Platelet distribution width: a novel prognostic marker in an internal medicine ward. J Community Hosp Intern Med. 2019;9(6):464–470. doi:10.1080/20009666.2019.1688095
   Web of Science ®Google Scholar
• Patel MS, Miranda-Nieves D, Chen J, Haller CA, Chaikof EL. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res. 2017;183:1–13. doi:10.1016/j.trsl.2016.11.007
   PubMed Web of Science ®Google Scholar
• André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Am Heart Assoc. 2002;2022:896–899.
   Google Scholar
• Poggi M, Engel D, Christ A, et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler Thromb Vasc Biol. 2011;31(10):2251–2260. doi:10.1161/ATVBAHA.111.231357
   PubMed Web of Science ®Google Scholar
• Russo I, Traversa M, Bonomo K, et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity. 2010;18(4):788–797. doi:10.1038/oby.2009.302
   PubMed Web of Science ®Google Scholar
• Zahran AM, Sayed SK, Abd El Hafeez HA, Khalifa WA, Mohamed NA, Hetta HF. Circulating microparticle subpopulation in metabolic syndrome: relation to oxidative stress and coagulation markers. Diabetes Metab Syndr Obes. 2019;12:485. doi:10.2147/DMSO.S191750
   PubMed Web of Science ®Google Scholar